Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Dover Digest.
Press releases published on August 18, 2025
RockWallet Secures Vermont Money Transmitter License, Expanding Digital Asset Services
RockWallet is Now Available in Vermont WILMINGTON, DE, UNITED STATES, August 18, 2025 /EINPresswire.com/ -- – RockWallet LLC, makers of the self-custodial, multi-currency wallet designed to make it simple to buy, use, store, and trade digital assets …
Eiffel Tower Nomination for Individual UNESCO World Heritage Status Announced
World Heritage: The Eiffel Tower Deserves Its Individual Inscription DE, UNITED STATES, August 18, 2025 /EINPresswire.com/ -- Already listed by UNESCO as part of the collective inscription of the “Banks of the Seine,” the Eiffel Tower benefits from …
Roadzen Addresses Inaccurate Reporting of Analyst Expectations in Q1 FY2026 Results
NEW YORK, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Roadzen Inc. (Nasdaq: RDZN) ("Roadzen" or the "Company”), a global leader in AI at the convergence of insurance and mobility, today clarified its fiscal first quarter 2026 results following inaccurate reporting …
Dogfish Head Debuts NEW Variety Pack Featuring Crowd-Sourced Fan-Favorites
MILTON, Del., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Dogfish Head invites drinkers to rediscover some of its first brews with the debut of its new, crowd-sourced Rewind Variety Pack. Offering a blast from the past, Dogfish Head’s Rewind Variety Pack is a …
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update
NRx Drug Development Grant of expanded Fast Track Designation for NRX-100 from the FDA for all indications and types of depression and related disorders based on its potential to satisfy an unmet medical need. Represents an approximately 10-fold expansion …
Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD)
-- Achieved Primary Endpoint with 30mg Dose of RE104 Demonstrating 23.0-Point Reduction from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Score on Day 7, a 5.8-Point Greater Reduction Than Patients Treated with 1.5mg Dose (p=0.0094) -- -- …